{"success":true,"data":{"pressRelease":{"id":"143416","rtpr_id":"nGNX2P45GM-20260915","ticker":"PFSA","exchange":"NASDAQ","all_tickers":["PFSA"],"title":"Profusa, Inc. Receives Nasdaq Compliance Determination","author":"Globe Newswire","published_at":"2026-09-15T10:00:00.117Z","article_body":"Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA)\n(the “Company”) announced today that on September 9, 2026, the Company\nreceived a letter (the “Compliance Determination Letter”) from The Nasdaq\nStock Market LLC (“Nasdaq”) confirming that the Company has demonstrated\ncompliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and\nNasdaq Listing Rule 5550(b)(1) (the “Equity Rule”).\n\nThe Company remains subject to a one-year Mandatory Panel Monitor (the\n“Monitoring Period”). If during the Monitoring Period the Company fails to\nsatisfy the equity rule, the company will not be provided the opportunity to\nsubmit a compliance plan; rather, Nasdaq will issue a delist determination,\nwhich the company may appeal by requesting a hearing. Such request would stay\nany further action by Nasdaq at least until the hearing is held and any\nextension granted by the Panel expires.\n\nThe Company intends to continue to monitor its compliance with all applicable\nNasdaq continued listing requirements.\n\nAbout Profusa, Inc.\n\nBased in Berkeley, California, Profusa is a digital health company pioneering\nnext-generation biosensor technologies, previously announced the signing of an\nOption Agreement (the “Agreement”) which provides Profusa the right and\noption, but not the obligation, subject to satisfaction of certain conditions,\nto acquire G3 Vision Labs, Inc. and its subsidiaries (“G3\").  Upon option\nexercising, the combined company is expected to operate as a public\ndiagnostics company.\n\nForward-Looking Statements\n\nCertain statements in this press release (this “Press Release”) may be\nconsidered “forward-looking statements” within the meaning of the “safe\nharbor” provisions of the United States Private Securities Litigation Reform\nAct of 1995. Forward-looking statements in this press release include, without\nlimitation, statements regarding the Company’s ability to maintain\ncompliance with Nasdaq listing standards, the Company’s plans to monitor its\ncontinued compliance, and the potential consequences of non-compliance during\nthe Mandatory Panel Monitor period. Forward-looking statements generally\nrelate to future events or future financial or operating performance of\nProfusa. In some cases, you can identify forward-looking statements by\nterminology such as “anticipate,” “believe,” “continue,”\n“could,” “estimate,” “expect,” “forecast,” “future,”\n“intend,” “may,” “might,” “plan,” “possible,”\n“potential,” “predict,” “project,” “propose,” “seek,”\n“should,” “strive,” “will,” or “would” or the negatives of\nthese terms or variations of them or similar terminology. Such forward-looking\nstatements are subject to risks, uncertainties, and other factors which may be\nbeyond the control of Profusa and could cause actual results to differ\nmaterially from those expressed or implied by such forward-looking statements.\nThese forward-looking statements are based upon estimates and assumptions\nthat, while considered reasonable by Profusa and its management, are\ninherently uncertain. Profusa cautions you that these statements are based on\na combination of facts and factors currently known and projections of the\nfuture, which are inherently uncertain. There are risks and uncertainties\ndescribed in the Company’s Annual Report on Form 10-K for the year ended\nDecember 31, 2025, filed with the SEC, and in other documents filed by Profusa\nfrom time to time with the SEC. These filings may identify and address other\nimportant risks and uncertainties that could cause actual events and results\nto differ materially from those contained in the forward-looking statements.\nProfusa cannot assure you that the forward-looking statements in this\ncommunication will prove to be accurate.\n\nInvestor and Media Contacts:\n\nemail: info@coreir.com \nphone: 1(212) 655-0924\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a8137a61-b858-48da-9e47-1f1bf8f6ddba)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2P45GM-20260915","title":"Profusa, Inc. Receives Nasdaq Compliance Determination","author":"Globe Newswire","ticker":"PFSA","created":"2026-09-15T10:00:00.117Z","tickers":["PFSA"],"exchange":"NASDAQ","article_body":"Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA)\n(the “Company”) announced today that on September 9, 2026, the Company\nreceived a letter (the “Compliance Determination Letter”) from The Nasdaq\nStock Market LLC (“Nasdaq”) confirming that the Company has demonstrated\ncompliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and\nNasdaq Listing Rule 5550(b)(1) (the “Equity Rule”).\n\nThe Company remains subject to a one-year Mandatory Panel Monitor (the\n“Monitoring Period”). If during the Monitoring Period the Company fails to\nsatisfy the equity rule, the company will not be provided the opportunity to\nsubmit a compliance plan; rather, Nasdaq will issue a delist determination,\nwhich the company may appeal by requesting a hearing. Such request would stay\nany further action by Nasdaq at least until the hearing is held and any\nextension granted by the Panel expires.\n\nThe Company intends to continue to monitor its compliance with all applicable\nNasdaq continued listing requirements.\n\nAbout Profusa, Inc.\n\nBased in Berkeley, California, Profusa is a digital health company pioneering\nnext-generation biosensor technologies, previously announced the signing of an\nOption Agreement (the “Agreement”) which provides Profusa the right and\noption, but not the obligation, subject to satisfaction of certain conditions,\nto acquire G3 Vision Labs, Inc. and its subsidiaries (“G3\").  Upon option\nexercising, the combined company is expected to operate as a public\ndiagnostics company.\n\nForward-Looking Statements\n\nCertain statements in this press release (this “Press Release”) may be\nconsidered “forward-looking statements” within the meaning of the “safe\nharbor” provisions of the United States Private Securities Litigation Reform\nAct of 1995. Forward-looking statements in this press release include, without\nlimitation, statements regarding the Company’s ability to maintain\ncompliance with Nasdaq listing standards, the Company’s plans to monitor its\ncontinued compliance, and the potential consequences of non-compliance during\nthe Mandatory Panel Monitor period. Forward-looking statements generally\nrelate to future events or future financial or operating performance of\nProfusa. In some cases, you can identify forward-looking statements by\nterminology such as “anticipate,” “believe,” “continue,”\n“could,” “estimate,” “expect,” “forecast,” “future,”\n“intend,” “may,” “might,” “plan,” “possible,”\n“potential,” “predict,” “project,” “propose,” “seek,”\n“should,” “strive,” “will,” or “would” or the negatives of\nthese terms or variations of them or similar terminology. Such forward-looking\nstatements are subject to risks, uncertainties, and other factors which may be\nbeyond the control of Profusa and could cause actual results to differ\nmaterially from those expressed or implied by such forward-looking statements.\nThese forward-looking statements are based upon estimates and assumptions\nthat, while considered reasonable by Profusa and its management, are\ninherently uncertain. Profusa cautions you that these statements are based on\na combination of facts and factors currently known and projections of the\nfuture, which are inherently uncertain. There are risks and uncertainties\ndescribed in the Company’s Annual Report on Form 10-K for the year ended\nDecember 31, 2025, filed with the SEC, and in other documents filed by Profusa\nfrom time to time with the SEC. These filings may identify and address other\nimportant risks and uncertainties that could cause actual events and results\nto differ materially from those contained in the forward-looking statements.\nProfusa cannot assure you that the forward-looking statements in this\ncommunication will prove to be accurate.\n\nInvestor and Media Contacts:\n\nemail: info@coreir.com \nphone: 1(212) 655-0924\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a8137a61-b858-48da-9e47-1f1bf8f6ddba)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-15T10:00:00.178475936Z","server_sent_at_ms":1789466400178},"received_at":"2026-09-15T10:00:00.236Z","source_url":null},"analysis":{"id":"132251","press_release_id":"143416","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["one-year Mandatory Panel Monitor: renewed equity-rule failure triggers a direct delist determination with no compliance-plan opportunity","history of prior listing deficiencies under both the bid price and equity rules; compliance may rest on a thin margin"],"eventType":"regulatory","narrative":"Profusa received a determination letter from Nasdaq dated September 9, 2026 confirming it has demonstrated compliance with both the Bid Price Rule (5550(a)(2)) and the Equity Rule (5550(b)(1)).\n\nThe company remains subject to a one-year Mandatory Panel Monitor, during which a renewed failure of the equity rule would result in a delist determination without a compliance-plan opportunity, appealable only by requesting a hearing that would stay further action.\n\nProfusa is a Berkeley, California-based digital health company pioneering biosensor technologies; it previously signed an option agreement to acquire G3 Vision Labs, with the combined company expected to operate as a public diagnostics company upon exercise.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Delisting overhang lifted for PFSA as Nasdaq confirms bid-price and equity compliance, but the one-year Mandatory Panel Monitor keeps a fast-track delist trigger alive."},"keyFigures":{"customDimensions":{"monitoring_period":"one-year Mandatory Panel Monitor","listing_rules_satisfied":["Nasdaq Listing Rule 5550(a)(2) Bid Price Rule","Nasdaq Listing Rule 5550(b)(1) Equity Rule"],"determination_letter_date":"2026-09-09"}},"quotedText":"remains subject to a one-year Mandatory Panel Monitor","namedEntities":{"people":[],"products":[],"companies":[{"name":"Profusa, Inc.","ticker":"PFSA","relationship":"filer"},{"name":"The Nasdaq Stock Market LLC","relationship":"exchange/regulator"},{"name":"G3 Vision Labs, Inc.","relationship":"option-agreement acquisition target (background)"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Nasdaq confirmed Profusa has regained compliance with both the Bid Price Rule and Equity Rule, removing the near-term delisting overhang for this micro-cap. However, the company remains under a one-year Mandatory Panel Monitor during which any renewed equity-rule failure triggers a direct delist determination, so listing risk is mitigated, not eliminated."},"tickerRelevance":{"others":[],"primary":"PFSA"},"globalImportance":22,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"listing-compliance-restoration","issuerAuthored":true,"ongoingMonitorRisk":true,"delistingRiskResolved":true}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Profusa received a determination letter from Nasdaq dated September 9, 2026 confirming it has demonstrated compliance with both the Bid Price Rule (5550(a)(2)) and the Equity Rule (5550(b)(1)).\n\nThe company remains subject to a one-year Mandatory Panel Monitor, during which a renewed failure of the equity rule would result in a delist determination without a compliance-plan opportunity, appealable only by requesting a hearing that would stay further action.\n\nProfusa is a Berkeley, California-based digital health company pioneering biosensor technologies; it previously signed an option agreement to acquire G3 Vision Labs, with the combined company expected to operate as a public diagnostics company upon exercise.","key_figures":{"customDimensions":{"monitoring_period":"one-year Mandatory Panel Monitor","listing_rules_satisfied":["Nasdaq Listing Rule 5550(a)(2) Bid Price Rule","Nasdaq Listing Rule 5550(b)(1) Equity Rule"],"determination_letter_date":"2026-09-09"}},"named_entities":{"people":[],"products":[],"companies":[{"name":"Profusa, Inc.","ticker":"PFSA","relationship":"filer"},{"name":"The Nasdaq Stock Market LLC","relationship":"exchange/regulator"},{"name":"G3 Vision Labs, Inc.","relationship":"option-agreement acquisition target (background)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-15T10:00:37.860Z","global_importance":22,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"listing-compliance-restoration","issuerAuthored":true,"ongoingMonitorRisk":true,"delistingRiskResolved":true}},"durationMs":37619,"modelName":"glm-5.3-flash"}}